These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37035469)

  • 41. Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE).
    Woodward N; De Boer RH; Redfern A; White M; Young J; Truman M; Beith J
    Clin Breast Cancer; 2019 Jun; 19(3):216-224. PubMed ID: 30922805
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer.
    Ishihara M; Mukai H; Nagai S; Mukohara T
    Int J Clin Oncol; 2009 Oct; 14(5):431-5. PubMed ID: 19856052
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer.
    Bae SJ; Kim JH; Ahn SG; Jeung HC; Sohn J; Kim GM; Kim MH; Kim SI; Park S; Park HS; Kim JY; Jeong J
    Front Oncol; 2021; 11():689587. PubMed ID: 34150658
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust®, and reference trastuzumab in healthy subjects.
    Farmahini Farahani M; Maghzi P; Jafari Aryan N; Payandemehr B; Soni M; Azhdarzadeh M
    Expert Opin Investig Drugs; 2020 Dec; 29(12):1443-1450. PubMed ID: 33016783
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
    Perez EA; Suman VJ; Davidson NE; Kaufman PA; Martino S; Dakhil SR; Ingle JN; Rodeheffer RJ; Gersh BJ; Jaffe AS
    J Clin Oncol; 2004 Sep; 22(18):3700-4. PubMed ID: 15365066
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer.
    Honda K; Takeshita K; Murotani K; Mitsuma A; Hayashi H; Tsunoda N; Kikumori T; Murohara T; Ando Y
    Breast Cancer; 2017 Mar; 24(2):312-318. PubMed ID: 27234030
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retrospective analysis of cardiac tolerability of concurrent administration of trastuzumab and anthracycline-based regimen for breast cancer, to address one-year-term issues in LVEF.
    Watanabe N; Otsuka S; Sasaki Y; Yuasa T; Shimada K
    Breast Dis; 2015; 35(4):253-61. PubMed ID: 26518668
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
    Yu AF; Yadav NU; Eaton AA; Lung BY; Thaler HT; Liu JE; Hudis CA; Dang CT; Steingart RM
    Oncologist; 2015 Oct; 20(10):1105-10. PubMed ID: 26240135
    [TBL] [Abstract][Full Text] [Related]  

  • 49. No Acute Changes in LVEF Observed With Concurrent Trastuzumab and Breast Radiation With Low Heart Doses.
    Bian SX; Korah MP; Whitaker TR; Ji L; Groshen S; Chung E
    Clin Breast Cancer; 2017 Nov; 17(7):510-515. PubMed ID: 28412326
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
    Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
    JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
    Guarneri V; Lenihan DJ; Valero V; Durand JB; Broglio K; Hess KR; Michaud LB; Gonzalez-Angulo AM; Hortobagyi GN; Esteva FJ
    J Clin Oncol; 2006 Sep; 24(25):4107-15. PubMed ID: 16908934
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of biosimilar trastuzumab MYL-1401O in HER2-positive breast cancer.
    Eser K; Sezer E; Erçolak V; İnal A
    Am J Manag Care; 2023 Feb; 29(2):e36-e42. PubMed ID: 36811986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab.
    Bouwer NI; Liesting C; Kofflard MJM; Brugts JJ; Kock MCJ; Kitzen JJEM; Levin MD; Boersma E
    Cardiovasc Ultrasound; 2021 Nov; 19(1):35. PubMed ID: 34753503
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab.
    Bouwer NI; Liesting C; Kofflard MJM; Sprangers-van Campen SM; Brugts JJ; Kitzen JJEM; Fouraux MA; Levin MD; Boersma E
    Cardiooncology; 2019; 5():4. PubMed ID: 32154011
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.
    Şendur MA; Aksoy S; Yorgun H; Ozdemir N; Yilmaz FM; Yazıcı O; Zungun C; Aytemir K; Zengin N; Altundag K
    Curr Med Res Opin; 2015 Mar; 31(3):547-56. PubMed ID: 25586297
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.
    Barroso-Sousa R; Tarantino P; Tayob N; Dang C; Yardley DA; Isakoff SJ; Valero V; Faggen M; Mulvey T; Bose R; Hu J; Weckstein D; Wolff AC; Reeder-Hayes K; Rugo HS; Ramaswamy B; Zuckerman D; Hart L; Gadi VK; Constantine M; Cheng K; Briccetti F; Schneider B; Garrett AM; Marcom K; Albain K; DeFusco P; Tung N; Ardman B; Nanda R; Jankowitz RC; Rimawi M; Abramson V; Pohlmann PR; Van Poznak C; Forero-Torres A; Liu M; Ruddy KJ; Zheng Y; Rosenberg SM; Gelber RD; Trippa L; Barry W; DeMeo M; Burstein H; Partridge A; Winer EP; Krop I; Tolaney SM
    NPJ Breast Cancer; 2022 Feb; 8(1):18. PubMed ID: 35173164
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.
    Jacquinot Q; Paget-Bailly S; Fumoleau P; Romieu G; Pierga JY; Espié M; Lortholary A; Nabholtz JM; Mercier CF; Pauporté I; Henriques J; Pivot X
    Breast; 2018 Oct; 41():1-7. PubMed ID: 29913374
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.
    Bianchi G; Albanell J; Eiermann W; Vitali G; Borquez D; Viganò L; Molina R; Raab G; Locatelli A; Vanhauwere B; Gianni L; Baselga J
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5944-51. PubMed ID: 14676119
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjuvant combined therapy with trastuzumab in patients with HER2‑ positive breast cancer and cardiac alterations: implications for optimal cardio‑oncology care.
    Grela-Wojewoda A; Niemiec J; Sas-Korczyńska B; Zemełka T; Puskulluoglu M; Wysocki WM; Wojewoda T; Pacholczak-Madej R; Adamczyk A; Mucha-Małecka A; Ziobro M; Konduracka E
    Pol Arch Intern Med; 2022 Apr; 132(4):. PubMed ID: 35089680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
    Stebbing J; Baranau Y; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Stroyakovskii D; Pikiel J; Eniu A; Komov D; Morar-Bolba G; Li RK; Rusyn A; Lee SJ; Lee SY; Esteva FJ
    Lancet Oncol; 2017 Jul; 18(7):917-928. PubMed ID: 28592386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.